N/A N=1,071 Postmarket Evaluation of the Phased Radio Frequency Ablation System (GOLD AF Registry)
Atrial Fibrillation
Primary: Estimate Phased RFA (Radio Frequency Ablation) Mid-term Success Rate — 185.1 Days
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=1,392 A Study of LY900014 in Participants With Type 1 Diabetes
Type 1 Diabetes Mellitus
Primary: Change From Baseline in Hemoglobin A1c (HbA1c) Efficacy Estimand at Week 26 — -0.13; 0.08; -0.05 Percentage of HbA1c — p=0.060
N/A N=18,822 Effects of a New Dispatcher-Assisted Basic Life Support Training Program
Out of Hospital Cardiac Arrest
Primary: Number of Participants Surviving to Hospital Discharge — 85; 551 Participants — p=0.34
Phase 2 N=34 Midostaurin and Azacitidine in Treating Elderly Patients With Acute Myelogenous Leukemia
Untreated Adult Acute Myeloid Leukemia
Primary: Maximum Tolerated Dose of Midostaurin in Combination With Azacitidine in Patients With Acute Myelogenous Leukemia (Phase I) — 75 mg/bid
Phase 2 N=80 Vortioxetine for Binge Eating Disorder
Binge Eating Disorder
Primary: Change in Number of Binge Eating Episodes — .93; .76 binge eating episodes
Phase 3 N=62 Study of Alirocumab (REGN727/SAR236553) in Patients With Heterozygous Familial Hypercholesterolemia (HeFH) Undergoing Low-density Lipoprotein (LDL) Apheresis Therapy
Heterozygous Familial Hypercholesterolemia
Primary: Change in Standardized Rate of Apheresis Treatments From Week 7 to Week 18 — 0.806; 0.128 Treatments — p=< 0.0001
Phase 1 N=16 A Study to Investigate the Pharmacokinetics (PK) of Modified Release (MR) Prototype Coated Tablet Formulations of GSK2982772
Autoimmune Diseases
Primary: Part A: Area Under the Curve From Time Zero to Infinity (AUC[0-inf]) of GSK2982772 240 mg in IR Formulation — 14.355 Hours*microgram per milliliter
Phase 3 N=331 Efficacy and Safety of Anti-MAP Therapy in Adult Crohn's Disease
Crohn's Disease
Primary: Remission at Week 26 — 61; 37 Participants — p=0.0048
Phase 3 N=150 Open-label Safety of Sodium Zirconium Cyclosilicate for up to 12 Months in Japanese Subjects With Hyperkalemia
Hyperkalemia
Primary: Number of Patients Who Experienced Adverse Events (AEs) in the MP — 131; 2; 27; 9 Participants
Phase 1 N=42 A Comparative Study of LY900014 to Insulin Lispro (Humalog) in Healthy Participants
Diabetes Mellitus, Type 2
Primary: Pharmacokinetics (PK): Insulin Lispro Area Under the Concentration Versus Time Curve (AUC) — 649; 656; 1400; 1450 picomole * hour per liter(pmol*/L) — p=0.5495
N/A N=282 Single or Double-layer Uterine Closure Techniques
Uterine Scar · Cesarean Section Complications · Cesarean Section; Dehiscence
Primary: Number of Participants With Niche Visualized by Saline Infusion Sonography — 40; 53; 25; 23 Participants — p=0.05
Phase 3 N=119 To Evaluate Oral Health and Quality of Life Associated With Use of a Denture Adhesive
Denture Retention
Primary: Gum Health Analysis by Change From Baseline in Overall Mean Scores of Participant Responses to the Gum Comfort Questionnaire After 12 Weeks — 4.1; 4.5; -0.6; -0.4 Score…
N/A N=4,329 Children's Healthy Living Community Randomized Trial
Obesity · Acanthosis Nigricans · Central Obesity
Primary: Change in Prevalence of Overweight and Obesity Using Body Mass Index Percentile for Age and Sex — -2.8; 1.4; -0.40 percentage of 2 to 8 yo children — p=0.02
Phase 2 N=170 Complementary Neurosteroid Intervention in Gulf War Illnesses (GWVI)
Fatigue · Musculoskeletal Pain · Cognitive Decline
Primary: Physical Component of the SF-36 — 2.04; 2.55; 1.23; 4.45 score on a scale
Phase 1 N=31 A Study of LY900014 in Japanese Participants With Type 1 Diabetes Mellitus
Diabetes Mellitus, Type 1
Primary: Pharmacokinetics (PK): Insulin Lispro Area Under the Concentration Curve Zero to 10 Hours (AUC 0-10h) Following Administration of Each Treatment Arm — 1930; 1980…